Page 322 - Traité de chimie thérapeutique 6 Médicaments antitumoraux

278 MEDICAMENTS INDUISANTDES MODIFICATIONS COVALENTES DE L'ADN

HOFFMANN J.S. et al., HMG1 protein inhibits the translesion synthesis of the major DNA
cisplatin adduct by cell extracts, J. Mol. Bio/, 1997, 270, 539-543.
MURRAY V. et al., Interaction of 11 cisplatin analogs with DNA : characteristic pattern of
damage with monofunctional analogs, Biochim. Biophys. Acta, 1997, 1354, 261-271.
DAMIA G. et al., Expression of genes involved in nucleotide excision repair and sensitivity
to cisplatin and melphalan in human cancer cell lines, Eur. J. Cancer, 1998, 34,1783-
1788.
JORDAN P.,CARMO-FONSECA M., Cisplatin inhibits synthesis of ribosomal RNA
in vivo, Nucleic Acids Res., 1998, 26, 2831-2836.
PANEVA E.G. et al., Interaction of histone H1 with cis-platinum modified DNA, Z. Natur-
forsch., C : Biosci., 1998, 53, 135-138.
SODHI A., SINGH R.A.K., Mechanism of NF-xB translocation in macrophages treated
in vitro with cisplatin, Immunol. Lett., 1998, 63, 9-17.
WOYNAROWSKI J.M. et al., Sequence- and region-specificity of oxaliplatin adducts in
naked and cellular DNA, Mol. Pharmaco/., 1998, 54, 770-777.
ZHAI X. et al., Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the
transcription factor human upstream binding factor, Biochemistry, 1998, 37, 16307-
16315.
CULLINANE C. et al., Inhibition of RNA polymerase Il transcription in human cell extracts
by cisplatin DNA damage, Biochemistry, 1999, 38, 6204-6212.
ISE T. et al., Transcription factor Y-box binding protein 1 binds preferentially to cisplatin-
modified DNA and interacts with proliferating cell nuclear antigen, Cancer Res., 1999,
59, 342-346.
JAMIESON E.R., LIPPARD S.J., Structure, recognition, and processing of cisplatin-DNA
adducts, Chem. Rev., 1999, 99, 2467-2498.
LI Q. et al., Modulation of excision repair cross complementation group 1 (ERCC-1)
mRNA expression by pharmacological agents in human ovarian carcinoma cells, Bio-
chem. Pharmacol., 1999, 57, 347-353.
OHNDORF U.M. et al., Basis for recognition of cisplatin-modified DNA by high-mobility-
group proteins, Nature, 1999, 399, 708-712.
REEDIJK J., Why does cisplatin reach guanine-N7 with competing S-donor ligands
available in the cell ? Chem. Rev., 1999, 99, 2499-2510.
VAISMAN A. et al., Effect of DNA polymerases and high mobility group protein 1 on the
carrier ligand specificity fortranslesion synthesis past platinum-DNA adducts, Bioche-
mistry, 1999, 38, 11026-11039.
BLANC et al., Caspase-3 is essential for procaspase-9 processing and cisplatin -indu-
ced apoptosis of MCF-7 breast cancer cells, Cancer Res., 2000, 60, 4386-4390.
SEKI K. et al., Cisplatin (CDDP) specifically induces apoptosis via sequential activation
of caspase-8, -3 and -6 in osteosarcoma, Cancer Chemother. Pharmacol., 2000, 45,
199-206.
SPINGLER B. et al., 2.4 A crystal structure of an oxaliplatin 1,2-d(GpG) intrastrand cross-
link in a DNA dodecamer duplex, Inorg. Chem., 2001, 40, 5596-5602.
SADOWITZ P.D. et al., Kinetics of cisplatin binding to cellular DNA and modulations by
thiol-blocking agents and thiol drugs, Drug Metab. Dispos. : the Bio/ogical Fate of
Chemicals, 2002, 30, 183-190.